164 related articles for article (PubMed ID: 38127899)
21. Immunity and Extracellular Matrix Characteristics of Breast Cancer Subtypes Based on Identification by T Helper Cells Profiling.
Zhou Y; Tian Q; Gao H; Zhu L; Zhang Y; Zhang C; Yang J; Wang B
Front Immunol; 2022; 13():859581. PubMed ID: 35795662
[TBL] [Abstract][Full Text] [Related]
22. MUC1-C integrates activation of the IFN-γ pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer.
Yamashita N; Long M; Fushimi A; Yamamoto M; Hata T; Hagiwara M; Bhattacharya A; Hu Q; Wong KK; Liu S; Kufe D
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33495298
[TBL] [Abstract][Full Text] [Related]
23. ICOS gene polymorphisms are associated with sporadic breast cancer: a case-control study.
Xu F; Li D; Zhang Q; Fu Z; Zhang J; Yuan W; Chen S; Pang D; Li D
BMC Cancer; 2011 Sep; 11():392. PubMed ID: 21917182
[TBL] [Abstract][Full Text] [Related]
24. Expression of immune checkpoint molecules programmed death protein 1, programmed death-ligand 1 and inducible T-cell co-stimulator in mycosis fungoides and Sézary syndrome: association with disease stage and clinical outcome.
Di Raimondo C; Rubio-Gonzalez B; Palmer J; Weisenburger DD; Zain J; Wu X; Han Z; Rosen ST; Song JY; Querfeld C
Br J Dermatol; 2022 Aug; 187(2):234-243. PubMed ID: 35194801
[TBL] [Abstract][Full Text] [Related]
25. An Antibody Targeting ICOS Increases Intratumoral Cytotoxic to Regulatory T-cell Ratio and Induces Tumor Regression.
Sainson RCA; Thotakura AK; Kosmac M; Borhis G; Parveen N; Kimber R; Carvalho J; Henderson SJ; Pryke KL; Okell T; O'Leary S; Ball S; Van Krinks C; Gamand L; Taggart E; Pring EJ; Ali H; Craig H; Wong VWY; Liang Q; Rowlands RJ; Lecointre M; Campbell J; Kirby I; Melvin D; Germaschewski V; Oelmann E; Quaratino S; McCourt M
Cancer Immunol Res; 2020 Dec; 8(12):1568-1582. PubMed ID: 32999002
[TBL] [Abstract][Full Text] [Related]
26. ICOS-Positive Regulatory T Cells in Hepatocellular Carcinoma: The Perspective from Digital Pathology Analysis.
Lu LC; Deantonio C; Palu CC; Lee YH; Mitchell LS; Cowan M; Corser M; Sherry L; Cheng AL; Quaratino S; Shao YY; Sainson RCA; Hsu CH
Oncology; 2022; 100(8):419-428. PubMed ID: 35709702
[TBL] [Abstract][Full Text] [Related]
27. Tumor microenvironment characterization in triple-negative breast cancer identifies prognostic gene signature.
Qin Y; Deng J; Zhang L; Yuan J; Yang H; Li Q
Aging (Albany NY); 2021 Feb; 13(4):5485-5505. PubMed ID: 33536349
[TBL] [Abstract][Full Text] [Related]
28. The inducible costimulator (ICOS) is critical for the development of human T(H)17 cells.
Paulos CM; Carpenito C; Plesa G; Suhoski MM; Varela-Rohena A; Golovina TN; Carroll RG; Riley JL; June CH
Sci Transl Med; 2010 Oct; 2(55):55ra78. PubMed ID: 20980695
[TBL] [Abstract][Full Text] [Related]
29. Immune Checkpoint Inhibition for Triple-Negative Breast Cancer: Current Landscape and Future Perspectives.
Yi H; Li Y; Tan Y; Fu S; Tang F; Deng X
Front Oncol; 2021; 11():648139. PubMed ID: 34094935
[TBL] [Abstract][Full Text] [Related]
30. A novel fatty-acid metabolism-based classification for triple negative breast cancer.
Yang X; Tang W; He Y; An H; Wang J
Aging (Albany NY); 2023 Feb; 15(4):1177-1198. PubMed ID: 36880837
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of immune checkpoint molecules in breast cancer.
Fang J; Chen F; Liu D; Gu F; Chen Z; Wang Y
Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32602545
[TBL] [Abstract][Full Text] [Related]
32. A novel model associated with tumor microenvironment on predicting prognosis and immunotherapy in triple negative breast cancer.
Zhang J; Zhang M; Tian Q; Yang J
Clin Exp Med; 2023 Nov; 23(7):3867-3881. PubMed ID: 37219794
[TBL] [Abstract][Full Text] [Related]
33. The Infiltration of ICOS
Zhang G; Xu Y; Zhou H
Pathol Oncol Res; 2020 Jan; 26(1):365-370. PubMed ID: 30361907
[TBL] [Abstract][Full Text] [Related]
34. TIGIT-related transcriptome profile and its association with tumor immune microenvironment in breast cancer.
Zhang Q; Gao C; Shao J; Wang Z
Biosci Rep; 2021 Mar; 41(3):. PubMed ID: 33721026
[TBL] [Abstract][Full Text] [Related]
35. Inducible T-Cell Costimulator Mediates Lymphocyte/Macrophage Interactions During Liver Repair.
Ramavath NN; Gadipudi LL; Provera A; Gigliotti LC; Boggio E; Bozzola C; Albano E; Dianzani U; Sutti S
Front Immunol; 2021; 12():786680. PubMed ID: 34925367
[TBL] [Abstract][Full Text] [Related]
36. Structural characterization of the ICOS/ICOS-L immune complex reveals high molecular mimicry by therapeutic antibodies.
Rujas E; Cui H; Sicard T; Semesi A; Julien JP
Nat Commun; 2020 Oct; 11(1):5066. PubMed ID: 33033255
[TBL] [Abstract][Full Text] [Related]
37. Tumor-infiltrating ICOS
Kajikawa H; Hirata M; Haruna M; Ueyama A; Hirose K; Kawashima A; Iwahori K; Matsunaga K; Toyosawa S; Uzawa N; Wada H
Anticancer Res; 2022 May; 42(5):2383-2393. PubMed ID: 35489733
[TBL] [Abstract][Full Text] [Related]
38. Agonizing over the Stimulatory Immune Checkpoint ICOS.
Lee JC; Fong L
Clin Cancer Res; 2022 Sep; 28(17):3633-3635. PubMed ID: 35792807
[TBL] [Abstract][Full Text] [Related]
39. CD8 T Cell Score as a Prognostic Biomarker for Triple Negative Breast Cancer.
Oshi M; Asaoka M; Tokumaru Y; Yan L; Matsuyama R; Ishikawa T; Endo I; Takabe K
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32971948
[TBL] [Abstract][Full Text] [Related]
40. ADAM12 abrogation alters immune cell infiltration and improves response to checkpoint blockade therapy in the T11 murine model of triple-negative breast cancer.
Wang G; Romero Y; Thevarajan I; Zolkiewska A
Oncoimmunology; 2023; 12(1):2158006. PubMed ID: 36545255
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
